GenFleet Therapeutics (Shanghai) Inc.
勁方醫藥科技(上海)股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2595)

ANNOUNCEMENT PURSUANT TO RULE 13.10 OF THE LISTING RULES

This announcement is made by GenFleet Therapeutics (Shanghai) Inc. (the "**Company**" or "**GenFleet**", together with its subsidiaries, the "**Group**") at the request of the Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"), pursuant to Rule 13.10 of the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**").

The board of directors of the Company (the "**Board**") has noted the increase in the price of the Company's shares recently and hereby informs the shareholders and potential investors of the Company about the latest business updates of the Group. The Company's clinical program evaluating GFH375 combined with cetuximab (the "**Clinical Program**"), was placed on the proposed Breakthrough Therapy Designation (BTD) list by the Center for Drug Evaluation of China's National Medical Products Administration on September 18, 2026. The combination therapy is intended for the treatment of metastatic colorectal cancer harboring KRAS G12D mutation in patients with disease progression following prior oxaliplatin-, fluoropyrimidine-, and irinotecan-based chemotherapy. The application of the Clinical Program for BTD was submitted on August 13, 2026, and the public comment period will conclude on September 24, 2026.

The Company had originally planned to make an announcement after the formal inclusion of the Clinical Program into the BTD list in accordance with market practice. In compliance with relevant terms of the Listing Rules, the Company hereby announces at this stage the regulatory progress related to the proposed inclusion of the Clinical Program into the BTD list. There remains a risk that the Clinical Program may not be granted BTD following the public comment period. Shareholders and potential investors of the Company are advised to exercise caution when dealing in, or contemplating dealing in, the securities of the Company. In view of the disclosure made in this announcement, the Company currently intends not to make a separate announcement proactively after the formal inclusion of the Clinical Program into the BTD list.

Having made such enquiries with respect to the Company as are reasonable in the circumstances, the Board confirms that, as at the date of this announcement, save as disclosed in this announcement, it is not aware of any reason for the rise in the share price, nor is it aware of any inside information that is required to be disclosed under Part XIVA of the Securities and Futures Ordinance in Chapter 571 of the Laws of Hong Kong.

Forward-looking Statements

Specific information in this announcement may contain or constitute forward-looking words that are not historical facts. They can be identified by using forward-looking terminology, such as "predict", "believe", "plan", "forecast", "expect", "will", "may", "should" and other words of similar meanings. Based on the management's current beliefs, plans, estimates and expectations of the Company's operation and market trends subject to changes beyond control, the forward-looking terminology reflects the Company's beliefs, plans, estimates and expectations of future development. Actual outcome in the future may differ significantly from forward-looking words owing to market, policy, and R&D uncertainties, among others. Subject to the above-mentioned uncertainties, the Company makes no expressed or implied guarantee as to the accuracy, completeness or feasibility of this presentation, and you are cautioned not to solely rely on such forward-looking words. Neither the company nor any of its directors, officers, employees, shareholders, agents, related parties, consultants or representatives will be liable to you or any other person for consequences resulting from using this presentation. Investors are advised to exercise due diligence with reference to the company's official disclosures for decision-making.

GLOSSARY OF TECHNICAL TERMS

"BTD"	Breakthrough Therapy Designation
"KRAS"	Kirsten RAS, a member of the RAS family of proteins

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market GFH375 successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
GenFleet Therapeutics (Shanghai) Inc.
Dr. Qiang LU
Chairman and Executive Director

Hong Kong, September 22, 2026

As at the date of this announcement, the Board of the Company comprises: (i) Dr. Qiang LU, Dr. Jiong LAN and Ms. ZHANG Wei as executive directors; (ii) Mr. ZHU Jingyang and Ms. TAO Sha as non-executive directors; and (iii) Ms. Christine Shaohua LU-WONG, Dr. ZHOU Demin and Mr. LI Bo as independent non-executive directors